- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
UNITAID was launched in 2006 at the United Nations General Assembly by the governments of Brazil, Chile, France, Norway and the United Kingdom to improve access to vital medicines, tests and prevention products for people living with HIV/AIDS, TB and malaria in low income countries. Its pioneering investments, financed significantly by an air ticket levy, have shaped the markets for paediatric and second line medicines for HIV/AIDS, new diagnostic tools to detect TB and the provision of ACTs to private sector outlets where up to 60% of people seek treatment for malaria in high burden countries. Reflecting on these accomplishments and looking to address gaps in the availability and affordability of life-saving products for the three diseases, UNITAID produced a new strategy for 2013-2016.
Keywords: HIV/AIDS, TB, malaria, medicines, diagnostics, paediatric, treatment
UNITAID’s Strategy 2013-2016 guides the organization’s response to HIV/AIDS, malaria and TB. In total, these global epidemics kill almost 4 million people every year. Forward looking and flexible, UNITAID collects intelligence on product markets for these diseases in order to inform its investments, which are implemented by the world’s top development organizations.
Keywords: HIV/AIDS, TB, malaria, medicines, diagnostics, prevention
TB is the leading cause of death among people living with HIV (PLHIV). One in five HIV-related deaths is caused by TB. Untreated TB in people with HIV can lead to death in weeks.
Keywords: TB, HIV, co-infection, treatment, discrimination, health care
The purpose of UNITAID is to contribute to the achievement of global long-term goals for HIV, tuberculosis and malaria through its interventions in product markets. These goals have determined the Strategic Objectives described in this Strategy for the coming four years and are shared by the international community at large.
Keywords: HIV/AIDS, TB, malaria, medicines, funding, diagnostics, prevention
AZD5847 belongs to the oxazolidinone class of compounds, which function as protein synthesis inhibitors and were first discovered in the mid- 1980s. Linezolid was the first compound of the oxazolidinone class to be approved for marketing and is most commonly used to treat drug-resistant TB. However, the use of linezolid has been limited by toxicity concerns, particularly haematological effects after periods of treatment over 14 days.
AZD5847 (previously referred to as AZD2563, generic name posizolid) is a modified analogue of the linezolid compound. AZD5847 was originally designed for treatment of gram-positive infections but was subsequently repurposed as an anti-TB agent. Like linezolid, AZD5847 has a bactericidal effect against mycobacterium TB in macrophages as well as in murine models of acute and chronic TB infection.
The patent landscape in Annex I of this report sets out the key patents and patent applications for bedaquiline, including their geographical patent coverage, as of June 2011. While every effort has been made to obtain comprehensive and accurate information on the status and geographical scope of the patents covering bedaquiline, in many countries patent information is not readily available to the public or not updated on a regular basis. In addition, some patent applications may have been published only after the searches were conducted. As such, there may be other relevant patents which have subsequently been published and which are not included in this landscape. Accordingly, the information provided herein is subject to the above disclaimers.
Keywords: HIV, TB, drugs, treatment, coverage
This is the eighteenth global report on tuberculosis (TB) published by WHO in a series that started in 1997. It provides a comprehensive and up-to-date assessment of the TB epidemic and progress in implementing and ﬁnancing TB prevention, care and control at global, regional and country levels using data reported by 197 countries and territories that account for over 99% of the world’s TB cases.
Just over two years remain before the end of 2015, the target deadline. This special supplement of the Global Tuberculosis Report 2013 summarizes the status of progress towards targets set within the MDG framework and for the response to TB/HIV and MDR-TB specifically (Table S2), and the actions needed to either move beyond or accelerate towards these targets. Snapshots are provided globally, regionally and for the 22 high-burden countries (HBCs) that have about 80% of the world’s TB cases (Figure S1) and that have received the greatest attention at the global level since 2000.
The 2013 Report on Tuberculosis Research Funding Trends: 2005–2012 presents eight years of funding data to characterize annual investments by the world’s leading donors to TB R&D. The report compares current spending in six areas of research with the corresponding R&D funding targets outlined in the Stop TB Partnership’s Global Plan to Stop TB 2011–2015 and shows how these levels of investment have changed over time since 2005, the baseline year. The analysis reveals that in all six research categories, actual spending falls far short of the investments required to develop and introduce new tools to fight TB.
The technology landscape highlights current and emerging tools for improved diagnosis of TB. The emphasis of this report is on NAAT products, where the most significant recent development has been seen. A variety of options, either commercially available or in late-stage development, are designed for detection of TB, first and/or second-line drug resistance, or for TB diagnosis and drug resistance combined. Commercialized technologies and those in late-stage development do hold promise in expanding the potential for TB diagnosis via NAATs. However, GeneXpert remains the leading technology in this area and is the last product endorsed by WHO in 2010. While a growing portfolio of TB NAAT assays are commercialized or in late-stage development, none is expected to be endorsed by WHO in 2013, and few tests are anticipated to have the necessary evidence base for endorsement over the next two to three years.
Keywords: TB, diagnostics, public health, drugs